Dr. Daver Discusses Use of MRD Assessment in Hematologic Malignancies

Naval G. Daver, MD
Published: Friday, Mar 01, 2019



Naval G. Daver, MD, oncologist, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the role of minimal residual disease (MRD) assessment in the treatment of patients with hematologic malignancies. Daver says MRD has emerged as an important part of predicting outcomes in these patients compared to previous standards in this setting.


Naval G. Daver, MD, oncologist, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the role of minimal residual disease (MRD) assessment in the treatment of patients with hematologic malignancies. Daver says MRD has emerged as an important part of predicting outcomes in these patients compared to previous standards in this setting.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x